You just read:

Independent Data Monitoring Committee recommends Phase III study of IMBRUVICA™ (ibrutinib) versus ofatumumab be stopped early based on statistically significant improvement in progression free survival and overall survival

News provided by

Pharmacyclics, Inc.

Jan 07, 2014, 09:30 ET